You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK)附屬新型法尼醇X受體激動劑研究表明耐受性良好
阿思達克 11-06 12:16
歌禮制藥-B(01672.HK)公佈,其全資附屬甘萊的新型法尼醇X受體(FXR)激動劑ASC42在健康受試者中的安全性、藥代動力學(PK)和藥效學(PD)數據,已在Drugs in R&D期刊上發表。 ASC42是一款由甘萊自主研發、擁有全球知識產權、有望成爲同類最佳(best-in-class)的新型高效選擇性非甾類FXR激動劑。研究表明,在健康受試者中,ASC42在給藥單次劑量高達100毫克以及14天多次日劑量高達15毫克的情況下,總體上是安全的,耐受性良好。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account